Practice guidelines for the treatment of hepatitis C: Recommendations from an AISF/SIMIT/SIMAST expert opinion meeting

Digestive and Liver Disease

Volumn 42, Issue 2, 2010, Pages 81-91

  Prati, Daniele ^a   Gasbarrini, Antonio ^a   Mazzotta, Francesco ^a   Sagnelli, Evangelista ^a   Carosi, Giampiero ^a   Abrescia, Nicola ^a   Alberti, Alfredo ^a   Ambu, Silvia ^a   Andreone, Piero ^a   Andriulli, Angelo ^a   Angelico, Mario ^a   Antonucci, Giorgio ^a   Ascione, Antonio ^a   Belli, Luca Saverio ^a   Bruno, Raffaele ^a   Bruno, Savino ^a   Burra, Patrizia ^a   Cammà, Calogero ^a   Caporaso, Nicola ^a   Cariti, Giuseppe ^a   Cillo, Umberto ^a   Coppola, Nicola ^a   Craxì, Antonio ^a   De Luca, Andrea ^a   De Martin, Eleonora ^a   Di Marco, Vito ^a   Fagiuoli, Stefano ^a   Ferrari, Carlo ^a   Gaeta, Giovanni Battista ^a   Galli, Massimo ^a   Grieco, Antonio ^a   Grossi, Paolo ^a   Licata, Anna ^a   Maida, Ivana ^a   Mangia, Alessandra ^a   Marino, Nicoletta ^a   Maserati, Renato ^a   Missale, Gabriele ^a   Mondelli, Mario ^a   Nasta, Paola ^a   Niro, Grazia ^a   Persico, Marcello ^a   Petrelli, Enzo ^a   Picciotto, Antonio ^a   Piscaglia, Fabio ^a   Pollicino, Teresa ^a   Puoti, Claudio ^a   Puoti, Massimo ^a   Raimondo, Giovanni ^a   Rumi, Maria Grazia ^a   Santantonio, Teresa ^a   Smedile, Antonina ^a   Squadrito, Giovanni ^a   Baroni, Gianluca Svegliati ^a   Taliani, Gloria ^a   Tavio, Marcello ^a   Toti, Mario ^a   Bonino, Ferruccio ^a   Brunetto, Maurizia Rossana ^a   Cacopardo, Bruno ^a   Caremani, Marcello ^a   Cauda, Roberto ^a   Colombo, Massimo ^a   Di Perri, Giovanni ^a   Donato, Francesca ^a   Farci, Patrizia ^a   Fattovich, Giovanna ^a   Filice, Gaetano ^a   Ghinelli, Florio ^a   Guadagnino, Vincenzo ^a   Lazzarin, Adriano ^a   Levrero, Massimo ^a   Licata, Giuseppe ^a   Orani, Anna ^a   Paffetti, Amerigo ^a   Pastore, Giuseppe ^a   Piccinino, Felice ^a   Pizzigallo, Eligio ^a   Pontisso, Patrizia ^a   Portelli, Vincenzo ^a   Rizzetto, Mario ^a   Rossi, Alessandro ^a   Stroffolini, Tommaso ^a   Ubaldi, Enzo ^a   Santantanio, Teresa ^a   more..

^a NONE

Author keywords

Acute hepatitis; Antiviral therapy; Chronic hepatitis; Cirrhosis; Elderly patients; HBV; HCV; HDV; HIV; Liver transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; BETA INTERFERON; DIDANOSINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; STAVUDINE; TELBIVUDINE; ZIDOVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; BONE MARROW TOXICITY; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DELTA AGENT HEPATITIS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG TOLERABILITY; ESOPHAGUS VARICES; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MIXED INFECTION; MONOTHERAPY; NEUTROPHIL COUNT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REINFECTION; RELAPSE; SEROCONVERSION; THERAPY DELAY; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE; VIREMIA; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 77958029477     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2009.08.001     Document Type: Article

References (77)

1. Alberti A, Bonino F, Bortolotti F, et al. Trattamento della epatite da HCV. Linee guida della Associazione Italiana per lo Studio del Fegato (AISF); 2004.
2. Licata A, Di Bona D, Schepis F, et al. When and how to treat acute hepatitis C? J Hepatol 2003;39:1056-62.
3. Santantonio T, Fasano M, Sinisi E, et al. Efficacy of a 24-week course of PEG-Interferon a-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 2005;42:329-33.
4. Santantonio T, Medda E, Ferrari C, et al. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis 2006;43(9):1154-9.
5. Santantonio T, Sinisi E, Guastadisegni A, et al. Natural course of Acute Hepatitis C: a long-term prospective study. Dig Liver Dis 2003;35:104-13.
6. Santantonio T, Wiegand J, Tilman Gerlach J. Acute hepatitis C: Current status and remaining challenges. J Hepatol 2008;49:625-33.
7. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39(4):1147-71.
8. Berg T, Von wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of Peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-97.
9. Dalgard O, Bjøro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004;40:1260-5.
10. Dalgard O, Bjøro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008;47(1):35-42.
11. Ferenci P, Berghoiz U, Laferi H, et al. 24 week treatment regimen with peginterferon alfa-2a (40 kd)plus ribavirin in HCV genotype 1 or 4 "super-responders" EASL abstract. J Hepatology 2006;44(Suppl. 2):8A.
12. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alpha-2a and ribavirin for 48 weeks in hepatitis C type 1 and 4 ptients with rapid virological response. Gastroentrology 2008;135:451-8.
13. Jensen D, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks Peginterferon alfa-2a ribavirin therapy. Hepatology 2006;43:954-60.
14. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352(25):2609-17.
15. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatits C genotype 1 patients: a randomized controlled trial. Hepatology 2008;47:43-50.
16. Sanchez-Tapias JM, DiagoM,Escartìn P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virusRNAat week 4 of treatment. Gastroenterology 2006;131:451-60.
17. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357(2):124-34.
18. von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129(2):522-7.
19. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with Peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006:1.
20. Ciancio A, Picciotto A, Giordanino C, et al. A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. Aliment Pharmacol Ther 2006;24(October (7)):1079-86.
21. Diago M, Crespo J, Olveira A, et al. Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. Aliment Pharmacol Ther 2007;26(October (8)):1131-8.
22. Jacobson IM, Gonzalez SA, Ahmed F, et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005;100(11):2453-62.
23. Jensen DM, Marcellin P, Freilich B, et al. Re-treatment of chronic hepatitis C non-responders to peginterferon alfa-2b: a randomized trial. Ann Intern Med 2009;150(April (8)):528-40.
24. Krawitt EL, Ashikaga T, Gordon SR, et al. Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J Hepatol 2005;43(2):243-9.
25. Maynard M, Pradat P, Bailly F, et al. Amantadine triple therapy for nonresponder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI). J Hepatol 2006;44(3):484-90.
26. Moucari R, Ripault MP, Oulès V, et al. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J Hepatol 2007;46(4):596-604.
27. Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis CWho Failed Interferon-alfa/Ribavirin Therapy. Gastroenterology 2009;136(5), 1618-28.32.
28. Sherman M, Yoshida EM, Deschenes M, et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 2006;55(11):1631-8.
29. Taliani G, Gemignani G, Ferrari C, et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology 2006;130(4):1098-106.
30. Abergel A, Hezode C, Leroy V, et al. Peginterferon-alfa2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis; amulticentre randomized trial comparing two doses of peginterferon-alfa2b. J Viral Hepat 2006;13:811-20.
31. Bruno S, Maisonneuve P, Pockros PJ, et al. Efficacy and safety of peg-interferon alfa-2a (40 Kd) plus ribavirin in HCV patients with complete cirrhosis (Knodell score F4). Hepatology 2006;44(4 S1):A332-3.
32. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579-87.
33. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. NEJM 2008;359:2429-41.
34. Di Marco V, Almasio PL, Ferraro D, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007;47:484-91.
35. Everson GT, Hoefs JC, Seeff LB, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology 2006;44:1675-84.
36. Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitisCvirus and decompensated cirrhosis: a controlled study. J Hepatol 2007;46(2):206-12.
37. Marrache F, Consigny Y, Ripault MP, et al. Safety and efficacy of Peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. J Viral Hepat 2005;12:421-8.
38. Roffi L, Colloredo G, Pioltelli P, et al. Pegylated interferon-alpha2b plus ribavirin: an efficacious and welltolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antivir Ther 2008;13:663-73.
39. Arjal RR, Burton Jr JR, Villamil F, Rosen HR. Review article: The treatment of hepatitis C virus recurrence after liver transplantation. Alimentary Pharmacol Ther 2007;26(2):127-40.
40. Berenguer M, Palau A, Aguilera V, et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008;8(3):679-87.
41. Bizollon T, Pradat P, Mabrut JY, et al. Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation. Am J Transplant 2007;7(2):448-53.
42. Carrión JA, Navasa M, García-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007;132(5):1746-56.
43. Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alpha-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005;41(Febuary (2)):289-98 [Erratum in: Hepatology 2005; 42(2):506].
44. Charlton M. Approach to recurrent hepatitis C following liver transplantation. Current Gastroenterology Reports 2007;9(1):23-30.
45. Cicinnati VR, Iacob S, Klein CG, et al. Ribavirin with either standard or pegylated interferon to treat recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther 2007;26(2):291-303.
46. Hanouneh IA, Miller C, Aucejo F, et al. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl 2008;14(1):53-8.
47. Shiffman M. Treating chronic hepatitis C virus after liver transplantation: balancing the risks against the chance for success. Liver Transpl 2007;13(8):1088-91.
48. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIVcoinfected patients. J Hepatol 2005;42:615-24.
49. Mauss S, Valenti W, De Pamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004;18:F21-5.
50. Nasta P, Gatti F, Puoti M. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. AIDS 2008 Apr 23;22(7):857-61.
51. Nunez M, Miralles C, Berdon MA, et al. The PRESCO study group: role of weightbased ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients. The PRESCO trial. AIDS Res Human Retroviruses 2007;23:972-82.
52. Opravil M, Sasadeusz J, Cooper DA, et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon alfa-2 (40 KD) plus ribavirin in patients with HIV-HCV co-infection. J Acquir Immune Def Syndr 2008;47: 36-49.
53. Rockstroh JK, Bhagani S, Benhamou Y, Bruno R. EACS Executive Committee European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Medicine 2008;9:82-8.
54. Romero-Gómez M, Del Mar Viloria M, Andrade RJ. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128(3):636-41.
55. Torriani FJ, Rodriguez-Torris M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV infected patients. N Engl J Med 2004;351:438-50.
56. Farci P, Chessa C, Balestrieri C, et al. Treatment of chronic hepatitis D. Med Virol 2007;14:58-63.
57. Gaeta GB, Precone DF, Cozzi-Lepri A, et al. Multiple viral infections. J Hepatol 2006;44:S108-13.
58. Pontisso P, Ruvoletto MG, Fattovich G, et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 1993;105:1529-33.
59. Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995;22:1101-8.
60. Gaeta GB, Stornaiuolo G, Precone DF, et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol 2003;39:1036-41.
61. Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or in combination with Ribavirin in Chronic Hepatitis Delta. Hepatology 2006;44:713-20.
62. Raimondo G, Brunetto MR, Pontisso P, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C viruscoinfected patients. Hepatology 2006;43:100-7.
63. Carosi G, Rizzetto M. Treatment of chronic hepatitis B: Recommendations from an Italian workshop. Dig Liver Dis G 2008;40:603-17.
64. Alessi N, Freni MA, Spadaro A, et al. Efficacy of interferon treatment (IFN) in elderly patients with chronic hepatitis C. Infez Med 2003;11(4):208-12.
65. Andreone P, et al. Infezione da HCV in età geriatrica, fase retrospettiva. In: AISF Annual Meeting. Oral Presentation. 2008.
66. Antonucci G, Longo MA, Angeletti C, et al. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol 2007;102(7):1383-91.
67. Bacosi M, Russo F, D'innocenzo S, et al. Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients. Hepatol Res 2002;22(3):231-9.
68. Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006;43(1):54-63.
69. Kumada T, Toyoda H, Honda T, et al. Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan. Intervirology 2006;49: 112-8.
70. Thabut D, Le Calvez S, Thibault V, et al. Hepatitis C in 6, 865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol 2006;101(6):1260-7.
71. Bacon BR. Treatment of patients with Hepatitis C and normal serum aminotransferase levels. Proc of the NIH Consensus Conference Management of Hepatitis C Hepatology 2002;36(Suppl. 1):S179-84.
72. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.
73. Puoti C, Guido M, Mangia A, et al. Clinical management of HCV carriers with normal aminotransferase levels. Dig Liver Dis 2003;35:362-9 [2006 update on http://www.webaisf.org/commconl.htm].
74. Puoti C, Pellicelli AM, Romano M, et al., on behalf of the Hospital Liver Club. Antiviral treatment ofHCVcarriers with normal ALT. 43rd Meeting EASL, poster # 826, J Hepatol 2008; 48: S309-310.
75. Snoeck E, Hadziyannis SJ, Puoti C, et al. Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferona-2a (40 KD) plus ribavirin. Liver Int 2008;28:61-71.
76. Strader DB, Wright T, Thomas DL, Seef LB. Diagnosis, management and treatment of hepatitis C. AASLD Practice Guideline. Hepatology 2004;39: 1147-71.
77. Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a [40 KD] and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004;127:1724-32.